Philip Burke Milam MD

Dermatology•Nashville, TN

Dermatologist

Join to View Full Profile

3601 The Vanderbilt ClinicNashville, TN 37232
Phone+1 615-322-3000

Education & Training

Ohio State University HospitalResidency, Dermatology, 2018 - 2021
Ohio State University Wexner Medical CenterFellowship, 2016 - 2018
University of Missouri-ColumbiaInternship, Internal Medicine, 2015 - 2016
East Tennessee State University James H. Quillen College of MedicineClass of 2015

Certifications & Licensure

TN State Medical License 2021 - 2025
OH State Medical License 2016 - 2022
MO State Medical License 2015 - 2016
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Outstanding Teaching Award University Missouri, Dept of Internal Medicine, 2016

Clinical Trials

Psoriasis Longitudinal Assessment and Registry Start of enrollment: 2007 Jun 21
ACTIVE_NOT_RECRUITING
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Start of enrollment: 2014 Jan 31
COMPLETED
PHASE2
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Start of enrollment: 2014 Sep 16
Completed
Phase 2
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Start of enrollment: 2014 Nov 03
Completed
Phase 3
The CorEvitas Psoriasis (PSO) Registry
ENROLLING_BY_INVITATION
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Start of enrollment: 2016 Jun 22
Completed
Phase 3
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Start of enrollment: 2016 Oct 20
COMPLETED
PHASE2
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Start of enrollment: 2017 May 04
Completed
Phase 2
The Ohio State University Dermatology Biorepository Start of enrollment: 2017 Apr 19
Recruiting
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Start of enrollment: 2017 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus Exercise.
Margo Waters, Allison Dobry, Stephanie T Le, Kanade Shinkai, Thomas M Beachkofsky
JAMA Dermatology. 2023-07-01
2 citations
Rare missense variants in the SH3 domain ofare associated with hidradenitis suppurativa.
David J Morales-Heil, Li Cao, Cheryl Sweeney, Anna Malara, Frank Brown
HGG Advances. 2023-04-13
Fibrous Proliferations in Posttransplant Kaposi Sarcoma
Kevin M Adams, Philip Milam, Alejandro A. Gru, Benjamin H. Kaffenberger
The Journal of Clinical and Aesthetic Dermatology. 2021-06-01

Books/Book Chapters

Dermatologic Surgery
Chapter: Dog-ear correction
Page 230 - 241Milam PB, Carr DREditors: Kantor J, Albertini JG, Bordeaux JS, Dzubow LM, Lawrence N, Miller SJ.McGraw-Hill Education, New YorkEdition 1,2018

Philip Burke Milam MD

Dr. Milam is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.